The Ideal Patient Population for the Use of Nivolumab in Treatment of NSCLC

July 7, 2016
Hossein Borghaei, DO

Hossein Borghaei, DO, chief, Thoracic Oncology, director, Lung Cancer Risk Assessment, associate professor in the Department of Hematology/Oncology, Fox Chase Cancer Center, discusses the ideal patient population that can potentially benefit from the use of nivolumab in the treatment of non-small cell lung cancer.